Revision 1

Store at -20C

#2695

IKKγ (DA10-12) Mouse mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H R	Endogenous	50	Mouse IgG1	#Q9Y6K9	8517

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

IKKγ (DA10-12) Mouse mAb detects endogenous levels of total IKKγ protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with full length human GST-IKKγ protein.

Background

The NF-κB/Rel transcription factors are present in the cytosol in an inactive state, complexed with the inhibitory IκB proteins (1-3). Most agents that activate NF-κB do so through a common pathway based on phosphorylation-induced, proteasome-mediated degradation of IκB (3-7). The key regulatory step in this pathway involves activation of a high molecular weight IκB kinase (IKK) complex whose catalysis is generally carried out by three tightly associated IKK subunits. IKKα and IKKβ serve as the catalytic subunits of the kinase and IKKγ serves as the regulatory subunit (8,9). Activation of IKK depends upon phosphorylation at Ser177 and Ser181 in the activation loop of IKKβ (Ser176 and Ser180 in IKKα), which causes conformational changes, resulting in kinase activation (10-13).
Activation of the NF-κB pathway by the T-cell lymphotrophic virus Tax protein or by TNF-α treatment leads to IKKβ-dependent phosphorylation of human IKKγ, primarily at Ser376 (14). In mice, mutation of the orthologous residue (Ser369) to alanine leads to enhanced IKKγ-mediated stimlulation of IKKβ kinase activity (15).

Background References

1. Baeuerle, P.A. and Baltimore, D. (1988) *Science* 242, 540-6.
2. Beg, A.A. and Baldwin, A.S. (1993) *Genes Dev* 7, 2064-70.
3. Finco, T.S. et al. (1994) *Proc Natl Acad Sci USA* 91, 11884-8.
4. Brown, K. et al. (1995) *Science* 267, 1485-8.
5. Brockman, J.A. et al. (1995) *Mol Cell Biol* 15, 2809-18.
6. Traenckner, E.B. et al. (1995) *EMBO J* 14, 2876-83.
7. Chen, Z.J. et al. (1996) *Cell* 84, 853-62.
8. Zandi, E. et al. (1997) *Cell* 91, 243-52.
9. Karin, M. (1999) *Oncogene* 18, 6867-74.
10. DiDonato, J.A. et al. (1997) *Nature* 388, 548-54.
11. Mercurio, F. et al. (1997) *Science* 278, 860-6.
12. Johnson, L.N. et al. (1996) *Cell* 85, 149-58.
13. Delhase, M. et al. (1999) *Science* 284, 309-13.
14. Carter, R.S. et al. (2003) *J Biol Chem* 278, 19642-8.
15. Prajapati, S. and Gaynor, R.B. (2002) *J Biol Chem* 277, 24331-9.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human **R:** Rat

Trademarks and Patents

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.